Oncology Billing & Revenue Cycle Management
Oncology medical billing for medical and radiation oncology practices
Medbilling RCM provides oncology medical billing for practices that run infusion suites and radiation departments. We handle drug billing, infusion administration coding and radiation therapy claims. Prior authorization and denial work run with every treatment. Each practice gets a dedicated account manager who covers insurance verification through payment posting. Service scope depends on your treatment mix, payer contracts and EHR.

Where Revenue Leaks
Where oncology claims lose revenue before they leave your office
Oncology stacks drug billing, infusion billing, and physician billing into one encounter. Each carries its own medical coding rules. Each of these errors passes silently if no one checks before the claim ships.
Infusion codes auto-bundle
Bill two initial infusion codes in the same tier and the payer auto-bundles both, even if the drugs ran hours apart.
Missing JW or JZ
Skip JW or JZ on a biologic vial and Medicare bounces it.
Wrong unit count
File the wrong unit count on J9271 and 200 billable units drop to 1.
Fraction cluster missed
Miss a radiation fraction cluster and that revenue sits uncollected.
Five-Phase Operating System
What the Revenue Control Framework checks on every oncology claim
Each claim runs through five checks in our oncology revenue cycle management framework. The framework catches drug math errors, missing modifiers and payer underpayments before the claim ships.
01
Dual-track verification
We verify coverage and secondary plans before each infusion cycle. For biologics, we build the PA from clinical notes. Our medical credentialing team tracks auth expiration per drug.
02
Attachment packaging
We pull start times, stop times, and IV access from nursing flowsheets inside your EHR. Biologics share infusion hierarchy rules with rheumatology billing. We sequence both the same way.
03
Claim cross-coding
We assign HCPCS J-codes, convert NDCs to 11-digit 5-4-2 format and calculate billing units per vial. JW goes on the wastage line. JZ confirms zero waste on the administered line.
04
Denial resolution
We classify every denial by its CARC/RARC code. CO-16 means resubmission with the corrected NDC. CO-197 means retroactive auth appeal. Our AR recovery team resolves aging balances.
05
Payment reconciliation
We reconcile every ERA against your contracted rates and the current quarter's ASP drug pricing file. If a payer underpaid a J-code claim, we catch the shortfall and file an appeal.
CPT/HCPCS Code Reference
Accurate codes and modifiers on every oncology encounter
Our oncology coding team assigns medical, radiation and immunotherapy codes for every encounter. We verify each code set against AMA CPT 2026 and NCCI bundling edits.

| Category | CPT/HCPCS | Billing notes |
|---|---|---|
| Chemo infusion admin | 96413, +96415, +96417, 96409/+96411 | One initial per encounter. Hierarchy: chemo > therapeutic > hydration. |
| Therapeutic/supportive | 96365, +96367, 96374/+96375, 96360/+96361 | Pre-meds billed as sequential (+96367) or push (+96375), never initial. |
| High-cost J-codes | J9271, J9299, J9035, J9312, J1442 | 11-digit NDC (5-4-2). JW for waste, JZ for zero. Unit = dose / descriptor. |
| CAR-T / biosimilars | Q2041, Q2042, Q5115, Q5118 | CAR-T per infusion event. Biosimilar matched to reference biologic. |
| Radiation oncology | 77263, 77301, 77334, 77373, 77427 | 77427 per 5 delivered fractions. 77301 bundles 77300 same day. |
| Hematology | 38220, 38221, 38222 | Bill 38222 for combined aspiration + biopsy. Don't unbundle. |
| Clinical trials | Mod Q0, Mod Q1, ICD-10 Z00.6 | Q1 for routine costs. Q0 for investigational. NCT in Box 19. |
| ICD-10 oncology | C18-C20, C34, C50, C61, Z51.11, Z51.0 | Primary site code supports medical necessity. Z51.11 for chemo encounter, Z51.0 for radiation. |
| Key modifiers | JW, JZ, Mod 25, Mod 59/X{EPSU}, TC/26 | JW/JZ mandatory on every single-dose container since Jan 2024. |
Clinical / Billing Split
Your team stays clinical. We handle the billing.
We don’t replace your clinical staff. We plug into your workflow as your oncology billing company.

EHR / OIS Compatibility
No revenue gap when you switch. Your oncology systems stay in place.
We work with oncology EHR platforms and radiation OIS systems in your practice. Claims process through both systems during transition. We confirm integration scope at onboarding.

Common Questions
Questions we hear from oncology practices before they sign
What reporting do we get on our oncology revenue?
Your account manager sends monthly reports on J-code collections, CARC denial rates, and JW/JZ compliance. Each report flags which drugs generate margin and which payers underpay against the ASP file. Numbers tie back to your contracted rates so you can renegotiate from data. Report detail depends on EHR and payer data.
How fast do claims go out after an infusion visit?
We scrub and submit claims within 48 hours of receiving a completed flowsheet. Drug unit calculations, NDC formatting, and modifier assignments happen the same day the encounter closes. If a claim needs prior authorization documentation, we attach it before submission instead of letting it pend. Turnaround depends on flowsheet completeness.
How do you prevent underpayments on high-cost drug claims?
We verify every drug unit calculation before the claim ships. J9271 (pembrolizumab) at 1 mg per unit means a 200 mg dose bills as 200 units. We convert each NDC to 5-4-2 format and cross-check it against the quarter's ASP file. Recovery depends on contract terms and appeal rights.
Do you support practices enrolled in the 340B drug pricing program?
We track 340B-eligible encounters separately from standard buy-and-bill claims. Your system flags qualifying patients under your 340B contract pharmacy or in-house dispensing. We apply the correct acquisition cost on each claim so your drug margin reflects the 340B discount. Split billing between 340B and non-340B encounters stays accurate across payers. Eligibility depends on covered entity registration.
How do you protect buy-and-bill drug margins?
We track wholesale acquisition cost against the current quarter's ASP allowance. Medicare pays ASP plus 6%, subject to the sequestration reduction. If a payer underpays, we catch it at posting and file an appeal. Margin depends on your acquisition cost and payer contract terms.
What does onboarding look like with a new oncology billing company?
We start with EHR/OIS access, your payer contracts, and your current flowsheet workflow. We configure J-code unit tables, NDC rules, and JW/JZ checks within days. PA tracking by drug goes live on the same schedule. Most practices fully transition in 5 business days.
How do you handle biosimilar and CAR-T billing?
We match each biosimilar to its reference biologic code before assigning the biosimilar-specific HCPCS. CAR-T therapies bill under their own codes separate from standard chemo administration. We check formulary coverage and prior auth with each payer before the claim ships. Formulary coverage varies by payer and plan.
Do you handle credentialing for new oncology providers?
Our credentialing team enrolls oncologists, nurse practitioners, and physician assistants with each payer before their first billable encounter. We track reattestation deadlines so enrollment stays current during treatment. A lapsed enrollment blocks claims for every patient that provider treats during the gap.
Ready when you are
See where your oncology revenue is getting stuck
We'll pull a sample of your oncology billing claims. The report covers your infusion hierarchy accuracy, JW/JZ compliance rate, and drug margin by J-code. No setup fees and long-term contract.
- Infusion hierarchy accuracy
- JW/JZ compliance rate
- Drug margin by J-code